Aggressive malignant peritoneal mesothelioma responds to treatment with Alimta (pemetrexed) and Platinol (cisplatin) chemotherapy, reports a study examining patient outcomes. But more studies are needed to…

A key approach to treating cancer these days is engineering immune T-cells to produce receptors on their surfaces that recognize cancer, so that the T-cells…

Zoledronic acid was only modestly active as a stand-alone therapy for advanced malignant pleural mesothelioma in a small Phase 2 pilot clinical trial. But researchers…

Activating a new mechanism to promote cell death could provide hope for better mesothelioma treatments, a Japanese study indicates. The research, ”Connexin 43 enhances Bax…

Combining immunotherapy, accelerated radiation and surgery can improve immune system response against malignant pleural mesothelioma, according to a study. Immunotherapies for solid tumors have become a…

A study that looked into France’s RENAPE Observational Registry, a database of rare peritoneal tumors, found that the presence of programmed death-ligand 1 (PD-L1) on…

It is safe for malignant mesothelioma patients to combine Tremelimumab and Imfinzi (durvalumab), according to a study to be presented at the 2017 American Society of Clinical…

A new study reports that a protein formerly identified as a potential therapeutic target in pleural mesothelioma, CXCR4, might not be a relevant approach for the…